Daxor Corporation Announces $9 Million Registered Direct Offering

Core Viewpoint - Daxor Corporation has entered into a definitive agreement for the purchase and sale of 765,958 shares of its common stock at a price of $11.75 per share, with expected gross proceeds of approximately $9 million [1][2]. Group 1: Offering Details - The offering is expected to close on or about January 26, 2026, subject to customary closing conditions [1]. - Lake Street Capital Markets, LLC is acting as the exclusive placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including working capital [2]. Group 3: Company Overview - Daxor Corporation addresses a significant issue in healthcare related to the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [5]. - The company manufactures and distributes a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data to improve patient outcomes [5]. - Daxor operates a state-of-the-art manufacturing facility in the U.S. and is positioned for accelerated market expansion [5].